Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 1, 2005, Pages 126-130

  Faundez, Mario ^a   Pino, Laura ^a   Letelier, Paula ^a   Ortiz, Carla ^a   López, Rodrigo ^a   Seguel, Claudia ^a   Ferreira, Jorge ^a   Pavani, Mario ^a   Morello, Antonio ^a   Maya, Juan Diego ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BENZNIDAZOLE; BUTHIONINE SULFOXIMINE; GLUTATHIONE; NIFURTIMOX; ROGANIL; THIOL DERIVATIVE; TRYPANOTHIONE;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENDOCYTOSIS; EPIMASTIGOTE; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE; VERO CELL;

ANIMALS; BUTHIONINE SULFOXIMINE; CERCOPITHECUS AETHIOPS; DRUG SYNERGISM; NIFURTIMOX; NITROIMIDAZOLES; PARASITIC SENSITIVITY TESTS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; VERO CELLS;

EID: 19944428950     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.1.126-130.2005     Document Type: Article

References (33)

1. Anderson, C. P., N. Keshelava, N. Satake, W. H. Meek, and C. P. Reynolds. 2000. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Med. Pediatr. Oncol. 35:659-662.
2. Arrick, B. A., O. W. Griffith, and A. Cerami. 1981. Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis. J. Exp. Med. 153:720-725.
3. Bailey, H. H., R. T. Mulcahy, K. D. Tutsch, R. Z. Arzoomanian, D. Alberti, M. B. Tor, G. Wilding, M. Pomplun, and D. R. Spriggs. 1994. Phase 1 clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J. Clin. Oncol. 12:194-205.
4. Bailey, H. H., G. Ripple, K. D. Tutsch, R. Z. Arzoomanian, D. Alberti, C. Feierabend, D. Mahvi, J. Schink, M. Pomplun, R. T. Mulcahy, and G. Wilding. 1997. Phase I study of continuous-infusion L-(S,R)-buthionine sulfoximine with intravenous melphalan. J. Natl. Cancer Inst. 89:1789-1796.
5. Calvert, P., K. S. Yao, T. C. Hamilton, and P. J. O'Dwyer. 1998 Clinical studies of reversal of drug resistance based on glutathione. Chem. Biol. Interact. 111-112:213-224.
6. Castro, J. A., and E. G. Diaz de Toranzo. 1988. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed. Environ. Sci. 1:19-33.
7. Contreras, V. T., J. M. Salles, N. Thomas, C. M. Morel, and S. Goldenberg. 1985. In vitro differentiation of Trypanosoma cruzi under chemically defined conditions. Mol. Biochem. Parasitol. 16:315-327.
8. Docampo, R., and S. N. Moreno. 1984. Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on Trypanosoma cruzi. Rev. Infect. Dis. 6:223-238.
9. Docampo, R., and A. O. M. Stoppani. 1979. Generation of superoxide anion and hydrogen peroxide induced by nifurtimox in Trypanosoma cruzi. Arch. Biochem. Biophys. 1911:317-321.
10. Docampo, R., S. N. J. Moreno, A. O. M. Stoppani, W. Leon, F. S. Cruz, F. Villalta, and R. F. A. Muniz. 1981. Mechanism of nifurtimox toxicity in different forms of Trypanosoma cruzi. Biochem. Pharmacol. 30:1947-1951.
11. Enanga, B., M. R. Ariyanayagam, M. L. Stewart, and M. P. Barrett. 2003. Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage. Antimicrob. Agents Chemother. 47:3368-3370.
12. Fairlamb, A. H., G. B. Henderson, C. J. Bacchi, and A. Cerami. 1987. In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Mol. Biochem. Parasitol. 24:185-191.
13. Filardi, L. S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 81:755-759.
14. Franke De Cazzulo, B. M., A. Bernacchi, M. I. Esteva, A. M. Ruiz, J. A. Castro, and J. J. Cazzulo. 1998. Trypanocidal effect of SKF525A, proadifen, on different developmental forms of Trypanosoma cruzi. Medicina (Buenos Aires) 58:415-418.
15. Griffith, O. W., and A. Meister. 1979. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254:7558-7560.
16. Hussein, A. S., and R. D. Walter. 1996. Purification and characterization of gamma-glutamyl transpeptidase from Ascaris mum. Mol. Biochem. Parasitol. 77:41-47.
17. Kapoor, P., M. Sachdev, and R. Madhubala. 2000. Inhibition of glutathione synthesis as a chemotherapeutic strategy for leishmaniasis. Trop. Med. Int. Health 5:435-442.
18. Maya, J. D., S. Bollo, L. J. Nuñez-Vergara, J. A. Squella, Y. Repetto, A. Morello, J. Perie, and G. Chauviere. 2003. Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem. Pharmacol. 65:999-1006.
19. Maya, J. D., A. Morello, Y. Repetto, A. Rodríguez, P. Puebla, E. Caballero, L. J. Núñez-Vergara, J. A Squella, M. E. Ortiz, J. Fuentealba, and A. San Feliciano. 2001. Novel antichagasic agents of the oxazolo(thiazolo)pyridine type. Relation between redox potential, lipophilicity, parasite culture growth and respiration inhibition. Exp. Parasitol. 99:1-6.
20. Maya, J. D., Y. Repetto, M. Agosin, J. M. Ojeda, R. Tellez, C. Gaule, and A. Morello. 1997. Effects of nifurtimox and benznidazole upon glutathione and trypanothione in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi. Mol. Biochem. Parasitol. 86, 101-106. 108.
21. Maya, J. D., A. Rodríguez, L. Pino, A. Pabón, J. Ferreira, M. Pavani, Y. Repetto, and A. Morello. 2004. Effects of buthionine sulfoximine nifurtimox and benznidazole upon trypanothione and metallothionein proteins in Trypanosoma cruzi. Biol. Res. 37:61-69.
22. Meister, A. 1995. Glutathione biosynthesis and its inhibition. Methods Enzymol. 252:26-30.
23. Meister, A., and O. W. Griffith. 1979. Effects of methionine sulfoximine analogs on the synthesis of glutamine and glutathione: possible chemotherapeutic implications. Cancer Treat. Rep. 63:1115-1121.
24. Moncada, C., Y. Repetto, J. Aldunate, M. E. Letelier, and A. Morello. 1989. Role of glutathione in the susceptibility of Trypanosoma cruzi to drugs. Comp. Biochem. Physiol. 94C:87-91.
25. Muelas-Serrano, S., J. J. Nogal-Ruiz, and A. Gómez-Barrio. 2000. Setting of a colorimetric method to determine the viability of Trypanosoma cruzi epimastigotes. Parasitol. Res. 86:999-1002.
26. Murta, S. M., R. T. Gazzinelli, Z. Brener, and A. J. Romanha. 1998. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol. Biochem. Parasitol. 93:203-214.
27. O'Dwyer, P. J., T. C. Hamilton, F. P. LaCreta, J. M. Gallo, D. Kilpatrick, T. Halbherr, J. Brennan, M. A. Bookman, J. Hofman, R. C. Young, R. L. Comis, and R. F. Ozols. 1996. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol. 14:249-256.
28. Olea-Azar, C., C. Rigol, F. Mendizábal, A. Morello, J. D. Maya, C: Moncada, E. Cabrera, R. di Maio, M. Gonzales, and H. Cerecetto. 2003. ESR-spin trapping studies of free radicals generated from nitrofuran derivative analogues of nifurtimox by electrochemical and Trypanosoma cruzi reduction. Free Rad. Res. 37:993-1001.
29. Repetto, Y., E. Opazo, J. D. Maya, M. Agosin, and A. Morello. 1996. Glutathione and trypanothione in several strains of Trypanosoma cruzi. Effect of drug. Comp. Biochem. Physiol. 115B:281-285.
30. Sipos, E. P., T. F. Witham, R. Ratan, P. C. Burger, J. Baraban, K. W. Li, S. Piantadosi, and H. Brem. 2001. L-Buthionine sulfoximine potentiates the antitumor effect of 4-hidroperoxycyclophosphamide when administered locally in a rat glioma model. Neurosurgery 48:392-400.
31. Vanhoefer, U., S. Cao, H. Minderman, K. Toth, B. S. Skenderis II, M. L. Slovak, and Y. M. Rustum. 1996. D,L-Buthionine-(S,R)-sulfoximine potentiates in vivo: the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin. Cancer Res. 2:1961-1968.
32. World Bank. 1993. World development report. Investing in health. Oxford University Press, New York, N.Y.
33. World Health Organization. 2002. Control of Chagas disease. W.H.O. Expert Committee. Second Report. Technical Report Series, no. 905. World Health Organization, Geneva, Switzerland.